Article Text

Download PDFPDF
Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results
  1. D van der Heijde1,
  2. L Klareskog2,
  3. M Boers3,
  4. R Landewé1,
  5. C Codreanu4,
  6. H D Bolosiu5,
  7. R Pedersen6,
  8. S Fatenejad6,
  9. for TEMPO Investigators
  1. 1Rheumatology Department, University Hospital, Maastricht, The Netherlands
  2. 2Rheumatology Unit, Department of Medicine, Karolinska Institute/Karolinska Hospital, Stockholm, Sweden
  3. 3Department of Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands
  4. 4Centrul Metodologic de Reumatologie, Bucuresti, Romania
  5. 5Clinica Reumatologica, Cluj-Napoca, Romania
  6. 6Wyeth Research, Collegeville, PA, USA
  1. Correspondence to:
    Professor D van der Heijde
    Rheumatology Department, University Hospital, Maastricht, PO Box 5800, 6202 AZ Maastricht, P Debyelaan 25, 6229 HX Maastricht, The Netherlands;


Objective: To assess methods to calculate achieving and sustaining remission in a double blind randomised trial in patients with RA who received etanercept, methotrexate, or an etanercept/methotrexate combination.

Methods: Remission was defined as DAS <1.6, DAS28 <2.6, and ACR70 response. Sustaining remission was analysed in three ways: (a) analysis of sustained DAS remission, DAS28 remission, or ACR70 response continuously for 6 months; (b) analysis of sustained remission appraised through a continuity rewarded scoring system, which is the weighted sum of all intervals in the study in which patients are in DAS or DAS28 remission; or (c) longitudinal modelling of remission odds using generalised estimating equations.

Results: Significantly more patients treated with the etanercept/methotrexate combination reached DAS remission (37%) than those treated with either methotrexate (14%) or etanercept (18%) alone (p<0.01). Results for DAS28 and for the ACR70 response were similar. Agreement between DAS remission and DAS28 remission was good, but agreement between either of these and the ACR70 response was less. Patients in DAS or DAS28 remission had a lower level of disease activity (fewer active joints, lower ESR) than those achieving ACR70 response; the converse was seen using pain VAS. The three methods were comparable for sustainability of remission and showed significant advantage for combination therapy, which increased the number and durability of remission periods.

Conclusions: DAS and DAS28 remission results were similar for assessing achieving and sustaining remission in RA, frequently differing from patients classified as ACR70 responders. The three methods of examining duration of remission produced comparable results.

  • ACR, American College of Rheumatology
  • ARA, American Rheumatism Association
  • ConRew, continuity rewarded
  • DAS, Disease Activity Score
  • ESR, erythrocyte sedimentation rate
  • FDA, Food and Drug Administration
  • GEE, generalised estimating equations
  • IQR, interquartile range
  • LOCF, last observation carried forward
  • MTX, methotrexate
  • OR, odds ratio
  • RA, rheumatoid arthritis
  • RCT, randomised controlled trial
  • TEMPO, Trial of Etanercept and Methotrexate with radiographic Patient Outcomes
  • VAS, visual analogue scale
  • etanercept
  • rheumatoid arthritis
  • sustained remission

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.